DOD Biotech PCL (BKK:DOD-R) 5-Year Sharpe Ratio: -0.80 (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:DOD-R DOD Biotech PCL BKK:DOD-R
67 GF Score
Price ฿0.97
GF Value ฿1.52
! 6 Warning Signs
View Full Analysis

What is DOD Biotech PCL 5-Year Sharpe Ratio?

DOD Biotech PCL BKK:DOD-R -5.84% 67 5-Year Sharpe Ratio is -0.80 as of Sep. 05, 2026. GuruFocus rates BKK:DOD-R with a GF Score™ of 67/100 and a GF Value™ of ฿1.52. The stock has 6 warning signs investors should review.

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2026-09-05), DOD Biotech PCL's 5-Year Sharpe Ratio is -0.80.

DOD Biotech PCL  (BKK:DOD-R) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

DOD Biotech PCL 5-Year Sharpe Ratio Related Terms

BKK:DOD-R vs KHC, GIS: 5-Year Sharpe Ratio Comparison

For the Packaged Foods subindustry, DOD Biotech PCL's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DOD Biotech PCL 5-Year Sharpe Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where DOD Biotech PCL's 5-Year Sharpe Ratio falls into.


BKK:DOD-R
67GF Score
DOD Biotech PCL BKK:DOD-R
5-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DOD Biotech PCL 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.

Frequently Asked Questions Learn more about 5-Year Sharpe Ratio →
What does a 5-Year Sharpe Ratio of -0.80 mean?
DOD Biotech PCL (BKK:DOD-R) has a 5-Year Sharpe Ratio of -0.80 as of Sep. 05, 2026. 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. View historical data for DOD Biotech PCL and its competitors.
Is DOD Biotech PCL's 5-Year Sharpe Ratio too high?
DOD Biotech PCL's current 5-Year Sharpe Ratio is -0.80. Overall, DOD Biotech PCL has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does DOD Biotech PCL's 5-Year Sharpe Ratio compare to KHC and GIS?
DOD Biotech PCL's 5-Year Sharpe Ratio of -0.80 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Sharpe Ratio for a Consumer Packaged Goods company?
A good 5-Year Sharpe Ratio depends on the Consumer Packaged Goods industry context. However, 5-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Sharpe Ratio mean?
A high 5-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. View historical data for DOD Biotech PCL and its competitors. DOD Biotech PCL's current 5-Year Sharpe Ratio is -0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DOD Biotech PCL stock overvalued right now?
DOD Biotech PCL (BKK:DOD-R) has a current 5-Year Sharpe Ratio of -0.80. The stock's GF Value™ is ฿1.52, compared to a current price of ฿0.97 — trading 36.4% below its estimated fair value. The current 5-Year Sharpe Ratio is -0.80. DOD Biotech PCL's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Sharpe Ratio calculated?
5-Year Sharpe Ratio is calculated from a company's financial statements. For DOD Biotech PCL (BKK:DOD-R), the current 5-Year Sharpe Ratio is -0.80 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DOD Biotech PCL (BKK:DOD-R) Overvalued in 2026?

Based on GuruFocus' analysis, DOD Biotech PCL stock appears to be undervalued. The current stock price of ฿0.97 is trading 36.4% below its estimated GF Value™ of ฿1.52.

Key valuation signals for BKK:DOD-R:

  • 5-Year Sharpe Ratio: -0.80
  • GF Value™: ฿1.52 vs. price of ฿0.97 (36.4% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the BKK:DOD-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DOD Biotech PCL Business Description

Other Exchanges DOD:Thailand
Address No. 111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000
DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The group is principally engaged in the supplement business. Its operations are carried on only in Thailand. Its products include: Capsule; Gel; Jelly; Powder for making drinks; Concentrated water extract (Shot Drink); Softgel; Tablet; Probiotics; Gummies; and Direct-to-Mouth Packaging.
67GF Score

Get the complete analysis for BKK:DOD-R

5-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿0.97
Price
฿1.52
GF Value